Novo Nordisk: Medicare Patients Preferring Oral GLP-1 Drugs Are Twice Those Preferring Injectables
0xBroomberg
Novo Nordisk survey data show Medicare beneficiaries with a clear preference choose oral pills over injections by a 2-to-1 ratio — a data point the company is positioning as its core argument in the market-share fight against Eli Lilly.
Where does the "2-to-1 preference" number come from?
Jamey Millar, Novo Nordisk's US head, said roughly three-quarters of Medicare beneficiaries have a clear preference on how they take medication.
Among those with a preference, people who chose oral pills outnumbered those who chose injections by roughly two to one.
This means → the elderly population's comfort with "swallowing a pill" far exceeds comfort with "getting a shot" — and this is survey data Novo Nordisk is putting on the table, not speculation.
Why do older patients lean toward oral?
Millar noted that many Medicare patients already take multiple oral medications daily — the routine of swallowing pills is built into their day.
In plain terms = when a row of pill bottles already sits on the counter, adding one more is effortless; a weekly injection is an entirely different experience.
This reflects a structural tilt shaped by existing medication habits, not just personal taste.
How is Novo Nordisk playing this?
The company is treating the US launch of oral Wegovy as a "drug-launch-level" event, with a dedicated rapid-response team already in place.
Millar's own words: "We are treating this like a drug launch."
This means → Novo Nordisk is not framing oral Wegovy as a line extension — it is deploying it as a new weapon to build awareness and capture share.
Medicare coverage lands in July — how big is the impact?
Starting July 1, Medicare will cover weight-loss drugs for obesity through a transitional program, capping patient co-pays at $50 per month.
Novo Nordisk itself is candid about the uncertainty: sales could jump immediately, or ramp gradually as elderly patients discuss the option with their doctors.
In plain terms = the policy opens the gate, but how fast the water flows depends on how quickly prescribing habits on the doctor side catch up.
In the oral-vs-injection fight, what is the real test?
Eli Lilly's injectable Zepbound has already overtaken Novo Nordisk to become the US obesity-market leader.
Novo Nordisk is betting on oral Wegovy to claw back share, and the "2-to-1 preference" data is its most critical piece of evidence.
This means → the test ahead is straightforward — whether patient preference actually converts into prescription volume growth. Only then does the oral-formulation story hold up.
Content is for reference only, not financial advice.